Skip to main content
. 2022 Aug 20;149(7):3739–3752. doi: 10.1007/s00432-022-04184-x

Fig. 3.

Fig. 3

Changing landscape of induction therapies prior to autologous stem cell transplantation in 540 patients divided into four cohorts over time from 1996 to 2019. VAD: vincristine, adriamycin and dexamethasone; VMP: bortezomib, melphalan and prednisone; BPV: bendamustine, prednisone and bortezomib, VD: bortezomib and dexamethasone; PAD: bortezomb, adriamycin and dexamethasone; VCD: bortezomid, cyclophosphamide and dexamethasone. Others: Regimens used up to and including 2010: VCAP (vincristine, cyclophosphamide, adriblastin, prednisolone), BP (bendamustine and prednisolone) and from 2011: VTD (bortezomib, thalidomide and dexamethasone), VRD (bortezomid, lenalidomide and dexamethasone), DVD (daratumumab, bortezomib and dexamethasone)